A Randomized, Double-Blind, Placebo-Controlled (Participants Aged 18 to 60 Years) and Open-Label (Participants Aged 4 to 17 Years), Phase 2/3 Trial to Evaluate the Immunogenicity and Safety of 2 Doses of a Dengue Tetravalent Vaccine (Live, Attenuated) (TDV) Administered Subcutaneously to Healthy Adults, Adolescents, and Children in Japan
Latest Information Update: 05 Jan 2026
At a glance
- Drugs Dengue tetravalent vaccine Takeda (Primary)
- Indications Dengue
- Focus Pharmacodynamics
- Sponsors Takeda
Most Recent Events
- 30 Dec 2025 Status changed from active, no longer recruiting to completed.
- 17 Mar 2025 Status changed from recruiting to active, no longer recruiting.
- 04 Feb 2025 Status changed from not yet recruiting to recruiting.